Table 3.
The league table for OS estimates interventions according to their relative effects in first part network analysis
| Apatorsen+Taxane (66.6%)a,b | ||||||||
|---|---|---|---|---|---|---|---|---|
| − 0.02 (− 0.41,0.37) | Atezolizumab (71.1%) | |||||||
| 0.22 (−0.35,0.80) | 0.24 (− 0.27,0.76) | Icrucumab+Taxane (36.3%) | ||||||
| 0.47 (−0.05,0.99) | 0.49 (0.03,0.95)b | 0.25 (−0.38,0.87) | Pazopanib (11.5%) | |||||
| −0.14 (− 0.53,0.25) | −0.12 (− 0.38,0.14) | −0.36 (− 0.88,0.15) | − 0.61 (− 1.07,-0.15) | Pemborlizumab (87.5%) | ||||
| − 0.09 (− 0.67,0.50) | −0.07 (− 0.60,0.46) | −0.31 (− 0.99,0.37) | −0.56 (− 1.19,0.08) | 0.05 (− 0.48,0.58) | Ramucirumab+Taxane (74.6%) | |||
| 0.22 (−0.10,0.55) | 0.24 (0.03,0.46) | −0.00 (− 0.47,0.47) | −0.25 (− 0.66,0.16) | 0.36 (0.15,0.57) | 0.31 (− 0.18,0.80) | Taxane (31.6%) | ||
| 0.41 (−0.11,0.93) | 0.43 (−0.02,0.89) | 0.19 (− 0.43,0.81) | −0.06 (− 0.63,0.52) | 0.55 (0.10,1.01) | 0.50 (− 0.13,1.13) | 0.19 (− 0.21,0.59) | Vandetanib+Taxane (16.2%) | |
| 0.07 (− 0.34,0.48) | 0.09 (− 0.11,0.30) | −0.15 (− 0.68,0.38) | −0.40 (− 0.88,0.08) | 0.21 (− 0.04,0.46) | 0.16 (− 0.39,0.71) | −0.15 (− 0.40,0.10) | −0.34 (− 0.82,0.13) | Vinflunine (54.6%) |
OS Overall Survival
aThe SUCRA probabilities are performed in brackets
bBold font means significant different